Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight

In participants with obesity or overweight from the SURMOUNT-1 trial, tirzepatide treatment significantly reduced body weight, fat mass and lean mass compared with placebo, while in post hoc analyses, the proportion of body weight lost as fat or lean mass was relatively consistent including in clinically relevant subgroups.